Gotowe bibliografie tematyczne / FK-506 (Drug)

Spis treści

  1. Artykuły w czasopismach
  2. Rozprawy doktorskie
  3. Książki
  4. Części książek

Gotowa bibliografia na temat „FK-506 (Drug)”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 19 lutego 2022

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „FK-506 (Drug)”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "FK-506 (Drug)"

1

Shaw, L. M., and K. L. Brayman. "FK-506 therapeutic drug monitoring." Clinical Chemistry 40, no. 12 (December 1, 1994): 2207–8. http://dx.doi.org/10.1093/clinchem/40.12.2207.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Winkler, M., B. Ringe, J. Baumann, M. Loss, K. Wonigeit, and R. Pichlmayr. "Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression." Clinical Chemistry 40, no. 12 (December 1, 1994): 2247–53. http://dx.doi.org/10.1093/clinchem/40.12.2247.

Pełny tekst źródła
Streszczenie:
Abstract By retrospective analysis of 13,000 blood samples obtained from 248 patients receiving FK 506 therapy, we compared the suitability of plasma with that of whole blood as the matrix for therapeutic drug monitoring of FK 506. The plasma concentrations did not correlate with the concentrations in whole blood (r = 0.56). In contrast to plasma samples (analyzed by enzyme immunoassay), FK 506 was detectable in all whole-blood samples (analyzed by enzyme immunoassay/microparticle enzyme immunoassay). The inter- and intraindividual variations of FK 506 measurements were greater in plasma than
Style APA, Harvard, Vancouver, ISO itp.
3

Dumont, F. J., M. J. Staruch, S. L. Koprak, J. J. Siekierka, C. S. Lin, R. Harrison, T. Sewell, V. M. Kindt, T. R. Beattie, and M. Wyvratt. "The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin." Journal of Experimental Medicine 176, no. 3 (September 1, 1992): 751–60. http://dx.doi.org/10.1084/jem.176.3.751.

Pełny tekst źródła
Streszczenie:
FK-506 inhibits Ca(2+)-dependent transcription of lymphokine genes in T cells, and thereby acts as a powerful immunosuppressant. However, its potential therapeutic applications may be seriously limited by several side effects, including nephrotoxicity and neurotoxicity. At present, it is unclear whether these immunosuppressive and toxic effects result from interference with related biochemical processes. FK-506 is known to interact with FK-binding protein-12 (FKBP-12), an abundant cytosolic protein with cis-trans peptidyl-prolyl isomerase activity (PPIase) activity. Because rapamycin (RAP) sim
Style APA, Harvard, Vancouver, ISO itp.
4

Rokaw, M. D., M. E. West, P. M. Palevsky, and J. P. Johnson. "FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells." American Journal of Physiology-Cell Physiology 271, no. 1 (July 1, 1996): C194—C202. http://dx.doi.org/10.1152/ajpcell.1996.271.1.c194.

Pełny tekst źródła
Streszczenie:
The immunosuppressants cyclosporin A (CyA), FK-506, and rapamycin (RAP) have multiple actions on target cells that appear to be mediated by interaction of drug-binding protein complexes. Both FK-506 and CyA, but not RAP, inhibit the Ca2(+)-dependent phosphatase, calcineurin, and in so doing have been found to inhibit Na(+)-K(+)-ATPase activity in various nephron segments. Of interest, FK-506 and RAP, but not CyA, are bound by the steroid receptor-associated FK-506-binding heat shock protein of 56 kDa, HSP56. To determine the physiological effect of this interaction on a steroid-mediated phenom
Style APA, Harvard, Vancouver, ISO itp.
5

Di Padova, F. E. "Pharmacology of CsA and FK-506." Perspectives in Drug Discovery and Design 2, no. 1 (August 1994): 49–56. http://dx.doi.org/10.1007/bf02171736.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Goulet, Mark T., Kathleen M. Rupprecht, Peter J. Sinclair, Matthew J. Wyvratt, and William H. Parsons. "The medicinal chemistry of FK-506." Perspectives in Drug Discovery and Design 2, no. 1 (August 1994): 145–62. http://dx.doi.org/10.1007/bf02171741.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Petros, Andrew M., Gerd Gemmecker, Placido Neri, Edward T. Olejniczak, David Nettesheim, Robert X. Xu, Earl G. Gubbins, Harriet Smith, and Stephen W. Fesik. "NMR studies of an FK-506 analog, [U-carbon-13]ascomycin, bound to FK-506-binding protein." Journal of Medicinal Chemistry 35, no. 13 (June 1992): 2467–73. http://dx.doi.org/10.1021/jm00091a015.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Kay, John E., Senam E. A. Doe, and C. Robin Benzie. "The mechanism of action of the immunosuppressive drug FK-506." Cellular Immunology 124, no. 1 (November 1989): 175–81. http://dx.doi.org/10.1016/0008-8749(89)90121-4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

O'connor, Stephen P., Robert L. Ellsworth, Mary Nallin Omstead, Rosalind G. Jenkins, and Louis Kaplan. "The preparation of 14C-labeled FK-506." Journal of Labelled Compounds and Radiopharmaceuticals 31, no. 2 (February 1992): 103–8. http://dx.doi.org/10.1002/jlcr.2580310205.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Jusko, William J. "Analysis of Tacrolimus (FK 506) in Relation to Therapeutic Drug Monitoring." Therapeutic Drug Monitoring 17, no. 6 (December 1995): 596–601. http://dx.doi.org/10.1097/00007691-199512000-00009.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "FK-506 (Drug)"

1

Karlsson, Håkan. "Influence of FK506 on certain aspects of lymphocyte activation and lymphocyte-endothelial cell interactions in vitro." Lund : Dept. of Medical Microbiology, Section of Clinical Immunology, Lund University, 1997. http://catalog.hathitrust.org/api/volumes/oclc/39799195.html.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Whitaker, Audie D. "The role of interferon-gamma in cyclosporine A or FK-506 treated L. major infected mice." Virtual Press, 1999. http://liblink.bsu.edu/uhtbin/catkey/1138295.

Pełny tekst źródła
Streszczenie:
Certain strains of mice, e.g. C57BL/6, are highly resistant to serious infections with the protozoan pathogen, Leishmania major, whereas other strains, e.g. BALB/c, are not. It has beenproposed that interferon gamma (IFN-y) is one of the most critical lymphokines produced in a protective response to these intracellular pathogens. IFN-y has been classified as a Thi lymphokine produced by the Thl subset of T lymphocytes which not only activates macrophages to kill the protozoa but also helps regulates the immune system overall to form a lasting immunity to the microorganism (4,19). Mice suscepti
Style APA, Harvard, Vancouver, ISO itp.
3

Potter, Shannon M. "The role of cyclosporin A, leptin, and FK-506 in Leishmania major infections in mice." Muncie, Ind. : Ball State University, 2009. http://cardinalscholar.bsu.edu/467.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Jones, Terence Edward. "Economically beneficial drug interactions with cyclosporin and tacroliumus : clinical studies in recipients of kidney and liver transplants." Title page, contents and abstract only, 2000. http://web4.library.adelaide.edu.au/theses/09PH/09phj79.pdf.

Pełny tekst źródła
Streszczenie:
Bibliography: leaves 234-257. Three separate clinical studies in organ transplant recipients are presented. The aims are to examine fundamental questions regarding the clinically and economically important pharmokinetic interaction between diltiazem and cyclosporin, an interaction widely utilised in organ transplantation. The data contained should assist the development of soundly based policies that will ensure a benefit exists before a sparing agent is coprescribed, and that the lowest effective dose of sparing agent is used.
Style APA, Harvard, Vancouver, ISO itp.
5

Soubhia, Rosa Maria Cordeiro. "Avaliação dos efeitos nefrotóxicos da associação do tacrolimus (FK 506) e antiinflamatórios não-hormonais em ratos." Faculdade de Medicina de São José do Rio Preto, 2005. http://bdtd.famerp.br/handle/tede/166.

Pełny tekst źródła
Streszczenie:
Made available in DSpace on 2016-01-26T12:51:42Z (GMT). No. of bitstreams: 1 rosasoubhia_tese.pdf: 792706 bytes, checksum: bba71696e22270729d09c3130cc047eb (MD5) Previous issue date: 2005-05-25<br>Introduction: Tacrolimus (FK 506) is a potent immunosuppressive drug that may cause nephrotoxicity decreasing the renal blood flow (RBF) and glomerular filtration rate (GFR). Conventional non-steroidal anti-inflammatory drugs (NSAIDs) may cause nephrotoxicity, interfering with renal hemodynamics and fluid and eletrolyte homeostasis. Recently, new selective COX-2 inhibitors have been developed produ
Style APA, Harvard, Vancouver, ISO itp.
6

Toske, Steven Gerald. "Part I : synthesis of azetidin-2-ones from pyrazolidin-3-ones ; Part II : synthesis of a subunit of the immunosuppressant FK-506." Thesis, 1993. http://hdl.handle.net/1957/35676.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Sinswat, Prapasri 1972. "Enhancing the delivery of poorly water soluble drugs using particle engineering technologies." 2006. http://hdl.handle.net/2152/13124.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Overhoff, Kirk Alan. "Improved oral bioavailability of poorly water soluble drugs using rapid freezing processes." 2006. http://hdl.handle.net/2152/13125.

Pełny tekst źródła
Streszczenie:
A growing number of therapeutic compounds currently being developed by pharmaceutical companies are poorly water soluble leading to limited and/or erratic bioavailability. The rate limiting step for absorption of these compounds is dependent on the dissolution and apparent solubility. Nanoparticle formation has been exploited as a method to improve the bioavailability of these poorly water soluble active pharmaceutical ingredients (API) by increasing the dissolution rates and apparent solubilities. The influence of hydrophilic stabilizers in powder compositions prepared by the spray freezing i
Style APA, Harvard, Vancouver, ISO itp.

Książki na temat "FK-506 (Drug)"

1

FK506 and organ transplantation. Austin: R.G. Landes, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Raptis, Dimitrios, and Manousos-Georgios Pramateftakis. Tacrolimus: Effectiveness, Safety and Drug Interactions. Nova Science Publishers, Incorporated, 2013.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Tacrolimus in organ transplantation: Prevention and treatment of allograft rejections. Lengerich: Pabst Science Publishers, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Toske, Steven Gerald. Part I: Synthesis of azetidin-2-ones from pyrazolidin-3-ones ; Part II : synthesis of a subunit of the immunosuppressant FK-506. 1993.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Thomas, Ruzicka, and Reitamo Sakari, eds. Tacrolimus ointment: A topical immunomodulator for atopic dermatitis. Berlin: Springer, 2004.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

(Editor), T. Ruzicka, and S. Reitamo (Editor), eds. Tacrolimus. Springer, 2003.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Tacrolimus ointment: A topical immunomodulator for atopic dermatitis. Berlin: Springer, 2003.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Części książek na temat "FK-506 (Drug)"

1

Rossaro, L., S. R. Dowd, V. Simplaceanu, R. Naccarato, D. H. Van Thiel, and C. Ho. "Effect of FK 506 and Cyclosporins on Model Membranes Studied by Nuclear Magnetic Resonance Spectroscopy." In Drugs and the Liver: High Risk Patients and Transplantation, 177–84. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1994-8_29.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

"Tacrolimus (FK-506)." In Drug Therapy in Dermatology, 172–81. CRC Press, 2000. http://dx.doi.org/10.1201/b14006-12.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

KOCIENSKI, PHILIP, MICHAEL STOCKS, and DAVID K. DONALD. "Recent Progress in Research on the Immunosuppressant FK-506." In Chirality in Drug Design and Synthesis, 131–65. Elsevier, 1990. http://dx.doi.org/10.1016/b978-0-12-136670-4.50014-x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „FK-506 (Drug)” dla poszczególnych typów źródeł:
Artykuły w czasopismach
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii